Lilly & Novo Nordisk's Oral Weight Loss Pills: A Market Battle

Eli Lilly and Novo Nordisk are vying for dominance in the burgeoning weight loss drug market, with their GLP-one medications. Novo Nordisk led the charge with semaglutide, approved for diabetes and obesity, while Lilly entered with tirzepatide, branded as Mounjaro and Zepbound. Both companies have now introduced oral drugs, shifting from injections to pills, with Novos oral Wegovy and Lillys Foundayo (orforglipron) hitting the market. Lillys Zepbound sales surged 80% to $4 billion, while Foundayo reached over 20,000 patients. Despite Novos early lead, Lillys Foundayo stands out due to its lack of food or drink restrictions and upcoming insurance coverage, indicating a promising future for both companies in this expanding market. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c4043d1cc2b71e29